Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects

Yang,Xi; Zhu,Yun; Ye,Dongxia; Liu,Yang; Sun,Hongying; Ruan,Min; Liu,Wei

doi:10.3892/mco.2016.868

Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects

Authors:
- Xi Yang
- Yun Zhu
- Dongxia Ye
- Yang Liu
- Hongying Sun
- Min Ruan
- Wei Liu
View Affiliations

Affiliations: Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China, Department of Stomatology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: April 20, 2016 https://doi.org/10.3892/mco.2016.868
Pages: 175-180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mouse double minute 2 (MDM2) gene is an important regulator of the p53 suppressor gene. To date, evidence concerning the association of the MDM2 single nucleotide polymorphism (SNP) 309T>G (rs2279744) with the risk of developing oral squamous cell carcinoma (OSCC) remains controversial. Therefore, a meta‑analysis of all the eligible studies was performed, in order to derive a more precise estimation of this association. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the degree of association in 5 previous studies, including a total of 1,369 OSCC cases and 2,167 controls. The overall analysis revealed a significant association between MDM2 SNP309 and OSCC risk in the heterozygote (TG vs. TT: OR=0.81; 95% CI: 0.68‑0.96; P=0.02) and dominant models (TG+GG vs. TT: OR=0.82; 95% CI: 0.69‑0.97; P=0.02). The subgroup analysis based on the source of the controls revealed a significant association between population‑based controls and the heterozygote model (TG vs. TT: OR=0.75; 95% CI: 0.62‑0.91; P=0.004), dominant model (TG+GG vs. TT: OR=0.76; 95% CI: 0.63‑0.91; P=0.003) and allele comparison (G vs. T: OR=0.89; 95% CI: 0.79‑0.99; P=0.04). Importantly, no evidence of publication bias or obvious heterogeneity were observed in the meta‑analysis. The results of the present study demonstrated a decreased risk of developing OSCC for the MDM2 SNP309 group, suggesting MDM2 SNP309 may be a protection-associated genetic variation for OSCC. Additional well-designed studies, with larger sample sizes, are required to further elucidate this association.

View Figures

View References

1	Rao Krishna SV, Mejia G, Roberts-Thomson K and Logan R: Epidemiology of oral cancer in Asia in the past decade-an update (2000–2012). Asian Pac J Cancer Prev. 14:5567–5577. 2013. View Article : Google Scholar : PubMed/NCBI
2	Petersen PE: Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol. 45:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
3	Zini A, Czerninski R and Sgan-Cohen HD: Oral cancer over four decades: Epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med. 39:299–305. 2010. View Article : Google Scholar : PubMed/NCBI
4	Liao G, Wang Y, Zhou YQ, Li TW, Zeng DQ, Zeng X, Li J, Dan HX and Chen QM: Host genetic susceptibility to oral cancer: Evidence from meta-analyses and pooled analyses. Oral Dis. 20:644–649. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
6	Bond GL, Hu W and Levine A: A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res. 65:5481–5484. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wo X, Han D, Sun H, Liu Y, Meng X, Bai J, Chen F, Yu Y, Jin Y and Fu S: MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis. J Genet Genomics. 38:341–350. 2011.PubMed/NCBI
8	Chen B, Cao L, Hu KW, Zhang JW, Meng XL and Xiong MM: MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers. Tumour Biol. 35:3431–3438. 2014. View Article : Google Scholar : PubMed/NCBI
9	Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ and Chang KW: MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol. 87:243–252. 2008. View Article : Google Scholar : PubMed/NCBI
10	Huang SF, Chen IH, Liao CT, Wang HM, Liou SH and Hsieh LL: Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 45:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
11	Misra C, Majumder M, Bajaj S, Ghosh S, Roy B and Roychoudhury S: Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog. 48:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hamid S, Yang YH, Peng KN, Ismail SM, Zain RB, Lim KP, Wan Mustafa WM, Abraham MT, Teo SH and Cheong SC: MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. Oral Oncol. 45:496–500. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chen X, Sturgis EM, Lei D, Dahlstrom K, Wei Q and Li G: Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res. 70:7199–7208. 2010. View Article : Google Scholar : PubMed/NCBI
14	Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, Trichopoulos D, Ahrens W, Pigeot I, Merletti F, et al: Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: The ARCAGE project. Cancer Res. 69:2956–2965. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Sturgis EM, Zhang Y, Huang Z, Zhou Q, Wei Q and Li G: Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 131:E251–E258. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Li S, Xiao HQ, Hu ZX, Xu YC and Huang Q: Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta-analysis. Oncol Lett. 6:1068–1078. 2013.PubMed/NCBI
17	Wang JG, Zhang Y and Xiao TL: Quantitative analysis of the association between CRP rs2808630 and rs1417938 polymorphisms and cancer risk. Oncol Lett. 9:994–998. 2015.PubMed/NCBI
18	Jiang LL and Ruan LW: Association between FOXP3 promoter polymorphisms and cancer risk: A meta-analysis. Oncol Lett. 8:2795–2799. 2014.PubMed/NCBI
19	Chen T, Yi SH, Liu XY and Liu ZG: Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk. Asian Pac J Cancer Prev. 13:4327–4330. 2012. View Article : Google Scholar : PubMed/NCBI
20	Liu G, Jiang D, Shen S and Yu L: Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta-analysis. Int J Urol. 19:914–920. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, He XJ, Wang HJ, Jiang XT and Tao HQ: The MDM2 309T>G polymorphism and ovarian cancer risk: A meta-analysis of 1534 cases and 2211 controls. PLoS One. 8:e550192013. View Article : Google Scholar : PubMed/NCBI
22	Manfredi JJ: The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 24:1580–1589. 2010. View Article : Google Scholar : PubMed/NCBI
23	Francis G, Dileep Kumar U, Nalinakumari KR, Jayasree K and Kannan S: Accumulation of inactive p53 protein in oral squamous cell carcinoma: Stabilization by protein interaction. Eur J Oral Sci. 121:21–28. 2013. View Article : Google Scholar : PubMed/NCBI
24	Millon R, Muller D, Schultz I, Salvi R, Ghnassia JP, Frebourg T, Wasylyk B and Abecassis J: Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance. Oral Oncol. 37:620–631. 2001. View Article : Google Scholar : PubMed/NCBI